We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
Patch is a modern plant shop for contemporary plant people. It helps in finding the most suitable plants and delivering them to the door. The company has delivered over 2,50,000 plants to over 82,000 customers in Paris and London. Patch has witnessed solid growth at +124% vs last year, reaching £4.48m in revenue. The company has a 4.6-star rating on TrustPilot and, it has been featured in The Times, The Telegraph etc. The funds will be used to expand across Europe, eliminate the middle-man and expand into the B2B market.

Pitch Rated

68%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £2,412,150
Little Earth Baby is an eco brand offering a range of baby products that are synthetic-free and natural. It aims to become a global market leader in the eco baby space by redesigning synthetic products to develop high-quality alternatives made from plants, not plastic. With the patent-pending designs and a growing loyal customer base, the company is well-placed to serve rising eco-conscious consumer trends. Additionally, Little Earth Baby appeared in the Telegraph's recommendations for Meghan & Harry's royal baby. The company also became a finalist in the Sleeping Bag category at the Australian non-toxic awards. 

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £147,010
StepLadder is a financial technology company dedicated to helping people buy their first home. The company asserts that it is tackling the housing crisis with its 'StepLadder Circles' that is based on the Rotating Savings and Credit Association model (ROSCA). Users have to state a monthly monetary contribution and a financial goal. The portal then adds them to a group of people with the same goal wherein all users contribute the same amount each month. The portal then randomly allocates one person in the circle each month the total contribution received. This repeats every month for the duration of the circle until everyone has received their deposit. It has awarded over £750,000 to members on its portal. The platform has featured in The Telegraph, Cosmopolitan, and The Independent. It also won 'Innovator of the Year' in the Women in Tech Awards 2020. StepLadder will use the investment received to improve its pan-UK growth via referral and ambassador programs.
days to go: Expired investment: £161,420
Glint is a proprietary multi-currency platform that allows users to buy, save, spend and send real gold and other currencies, digitally with its application. The company asserts that its scalable technology enables its clients to use their currencies such as GBP, USD, EUR and Gold, with Glint's UK, EU and US-issued Mastercards in 210 countries worldwide. Glint also points out that its Peer-to-Peer (P2P) Service, Glint It!, allows clients to send and receive gold and currency between Glint accounts in over 160 countries. The company has raised £20 million in equity funding to date, reached 79,000 registered clients, and overseen over £158 million worth of transactions on its platform. Glint will use the investment to maximise revenue, organically grow its business, increase its registered customer base to 250,000 in 2021, and hire key personnel across various portfolios.

Pitch Rated

80%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £3,072,539
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go: Expired investment: £3,768,260
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph